跳至主要内容
临床试验/JPRN-UMIN000032675
JPRN-UMIN000032675已完成2 期

Multicenter clinical trials to determine the efficacy and safety of consolidation and maintenance therapy with ixazomib, lenalidomide, dexamethasone (IRd) therapy in transplant-ineligible multiple myeloma. - prospective trial of ixazomib, lenalidomide, dexamethasone (IRd) therapy in transplant-ineligible multiple myeloma

Akita University hosipital0 个研究点目标入组 41 人开始时间: 2018年6月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
41

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
65years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1 relapsed myeloma 2 previous treatment history of ixazomib 3 not tolerable to lenalidomide, bortezomib, dexamethasone 4 with Grade 2 or higher peripheral neuropathy 5 pregnancy 6 Abnormality of blood test 7 CNS involvement 8 Plasma cell leukemia 9 with severe infection 10 with intestinal pneumoniae 11 with double and more cancer 12 without consent of blood transfusion 13 and other

研究者

发起方
Akita University hosipital

相似试验